Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (23248)	7/15/1998 6:14:00 PM
From: Andreas Helke	Read Replies (1) \| Respond to of 32384

The news that EntreMeds angiostatin and endostatin work better when they are combined with radiation offers interesting possibilities for Ligand. news.stocksmart.com I imagine that a combination of EntreMeds angiogenesis inhibitors with Ligands retinoids could be a powerful and non toxic anti cancer weapon. In the ideal world according to my portfolio that combination would boost the sales and market caps of both companies. Andreas

To: Henry Niman who wrote (23248)	7/15/1998 6:31:00 PM
From: medsunman	Read Replies (1) \| Respond to of 32384

Henry, what's your best guess as to when or how soon the FDA may act with respect to the Ontak NDA? Thanks, Medsunman

To: Henry Niman who wrote (23248)	7/15/1998 7:30:00 PM
From: Mudcat	Read Replies (2) \| Respond to of 32384

<Robinson's comments on SBH "gobbling up" LGND's targets > Henry, can you explain the above statement. What does it mean monetarily to lgnd? Does Lgnd get an up front milestone for each target "gobbled up"?

To: Henry Niman who wrote (23248)	7/16/1998 11:55:00 AM
From: Void	Read Replies (1) \| Respond to of 32384

re: GCSF mimic <<As I said in February, I think that LGND does have a human-active compound(s) and it is in pre-clinical testing (which seems to be borne out by the pipeline table at home.att.net which indicates that a compound has been identified and SELECTED.>> You may be right in that LGND has alternate compounds they are testing. However, to say that LGND has human-active compounds in pre-clinical testing is making quite a stand since the definition of pre-clinical testing is that it is not yet being tested in humans(aside from maybe some in-vitro work). So, whether or not any will be human-active is very much YET TO BE DETERMINED. Also, pipelines models put out by companies. (In fact, anything published by companies aside from the 10Q and articles in peer reviewed journals)are little more than marketing tools and should not be taken as fact. Regards, V